Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansa Biopharma AB ( (SE:HNSA) ) has issued an announcement.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, and CFO, Evan Ballantyne, will attend the 2025 Truist Securities Biopharma Symposium in New York. Aguiar-Lucander will also present at the Stifel 2025 Healthcare Conference and the SEB Healthcare Seminar 2025. These appearances highlight Hansa’s active engagement with the investment community and underscore its strategic focus on expanding its presence in the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK132.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy aiding kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm.
Average Trading Volume: 675,707
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.09B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.